Recent advances in the management of patients with non‐muscle‐invasive bladder cancer using a multidisciplinary approach: Practical recommendations from the spanish oncology genitourinary (sogug) working group

Abstract

On the basis of the discussion of the current state of research on relevant topics of non-muscle‐invasive bladder cancer (NMIBC) among a group of experts of the Spanish Oncology Gen-itourinary (SOGUG) Working Group, recommendations were proposed to overcome the challenges posed by the management of NMIBC in clinical practice. A unified definition of the term ‘microhe-maturia’ and the profile of the patient at risk are needed. Establishing a ‘hematuria clinic’ would contribute to a centralized and more efficient evaluation of patients with this clinical sign. Second or repeated transurethral resection (re‐TUR) needs to be defined, including the time window after the first procedure within which re‐TUR should be performed. Complete tumor resection is man-datory when feasible, with specification of the presence or absence of muscle. Budding should be used as a classification system, and stratification of T1 tumors especially in extensive and deep tu-mors, is advisable. The percentage of the high‐grade component should always be reported, and, in multiple tumors, grades should be reported separately. Luminal and basal subtypes can be identi-fied because of possibly different clinical outcomes. Molecular subtypes and immunotherapy are incorporated in the management of muscle‐invasive bladder cancer but data on NMIBC are still preliminary.